| Literature DB >> 26635779 |
Haroldo C de Oliveira1, Patrícia A Assato1, Caroline M Marcos1, Liliana Scorzoni1, Ana C A de Paula E Silva1, Julhiany De Fátima Da Silva1, Junya de Lacorte Singulani1, Kaila M Alarcon1, Ana M Fusco-Almeida1, Maria J S Mendes-Giannini1.
Abstract
Paracoccidioides brasiliensis and P. lutzii are etiologic agents of paracoccidioidomycosis (PCM), an important endemic mycosis in Latin America. During its evolution, these fungi have developed characteristics and mechanisms that allow their growth in adverse conditions within their host through which they efficiently cause disease. This process is multi-factorial and involves host-pathogen interactions (adaptation, adhesion, and invasion), as well as fungal virulence and host immune response. In this review, we demonstrated the glycoproteins and polysaccharides network, which composes the cell wall of Paracoccidioides spp. These are important for the change of conidia or mycelial (26°C) to parasitic yeast (37°C). The morphological switch, a mechanism for the pathogen to adapt and thrive inside the host, is obligatory for the establishment of the infection and seems to be related to pathogenicity. For these fungi, one of the most important steps during the interaction with the host is the adhesion. Cell surface proteins called adhesins, responsible for the first contact with host cells, contribute to host colonization and invasion by mediating this process. These fungi also present the capacity to form biofilm and through which they may evade the host's immune system. During infection, Paracoccidioides spp. can interact with different host cell types and has the ability to modulate the host's adaptive and/or innate immune response. In addition, it participates and interferes in the coagulation system and phenomena like cytoskeletal rearrangement and apoptosis. In recent years, Paracoccidioides spp. have had their endemic areas expanding in correlation with the expansion of agriculture. In response, several studies were developed to understand the infection using in vitro and in vivo systems, including alternative non-mammal models. Moreover, new advances were made in treating these infections using both well-established and new antifungal agents. These included natural and/or derivate synthetic substances as well as vaccines, peptides, and anti-adhesins sera. Because of all the advances in the PCM study, this review has the objective to summarize all of the recent discoveries on Paracoccidioides-host interaction, with particular emphasis on fungi surface proteins (molecules that play a fundamental role in the adhesion and/or dissemination of the fungi to host-cells), as well as advances in the treatment of PCM with new and well-established antifungal agents and approaches.Entities:
Keywords: Paracoccidioides brasiliensis; Paracoccidioides lutzii; Paracoccidioides pathogenicity and virulence; fungi–host interaction; paracoccidioidomycosis
Year: 2015 PMID: 26635779 PMCID: PMC4658449 DOI: 10.3389/fmicb.2015.01319
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Occurrence of paracoccidioidomycosis in the Brazilian territory raised by eco-epidemiological studies.
| State | Region | Period | Number of cases | Gender/age | Reference |
|---|---|---|---|---|---|
| Parana | Western | 2008–2009 | 102 | 72 male and 30 female/18–81 years | |
| Sao Paulo | Southeast | 1960–1999 | 1.000 | 858 male and 142 female/03–80 years | |
| Amazon | North | 1997–2012 | 2.163 | 1.951 males and 211 females/03–81 years | |
| Sao Paulo | Southeast | 1988–1996 | 584 | 492 males and 92 females/05–87 years | |
| Rio Grande do Sul | South | 1966–2009 | 123 | 104 males and 17 females/02–97 years |
Summary of studies related to dimorphism of Paracoccidioides genus.
| Condition | Approach (isolate) | Target | Observation | Reference |
|---|---|---|---|---|
| Mycelium-to-yeast transition | Pharmacologycal tools – inhibition with geldanamycin ( | Hsp90 | Up-regulated | |
| Mycelium-to-yeast | Real-time reverse transcription-polymerase chain reaction | Hsp90/AOX/GS1 | Up-regulated | |
| Mycelium-to-yeast transition | Pharmacologycal tools – inhibition with CsA, a calcineurin inhibitor cyclosporine A ( | Calcineurin | Transition to the yeast form was blocked before the blastoconidial budding stage | |
| Mycelium-to-yeast transition | Transcriptional profiling and pharmacological tools – 4-HPPD inhibitor ( | 4-hydroxyl-phenyl pyruvate dioxygenase (4-HPPD) | Up-regulated | |
| Mycelium-to-yeast | Pharmacologycal tools – inhibition with benzohydroxamic acid – inhibitor of AOX ( | AOX | Delayed the M-Y transition | |
| Yeast-mycelium germination and mycelium/conidia-to-yeast transition | Antisense RNA technology ( | AOX | Delayed the Y-M transition | |
| Mycelium-to-yeast transition | Transcriptional response to 17-β-estradiol treatment ( | Chitin synthase | Down-regulated in response to estradiol | |
| Mycelium-to-yeast transition | 1007 ESTs from a transition cDNA library ( | Two chitinases | Up-expressed | |
| Mycelium-to-yeast transition | Gene expression in the presence or absence of 17-β-estradiol ( | Rho-GTPase components | Down-regulated | |
| Mycelium-to-yeast and yeast-to-mycelia | Pharmacological approach – using tunicamycin (TM) | N-glycosylation | TM treatment interferes the transition in both directions by interference in the activity of α-1,4 amylase (involved in the biosynthesis of α-1,3 glucan) | |
| Mycelium-to-yeast | Real-time ( | Phospholipase (PLB) | Up-regulation in mycelial cells |